Ansa Biotechnologies vs Figma
Side-by-side comparison of AI visibility scores, market position, and capabilities
Enzymatic DNA synthesis company using TdT enzymes to write longer, higher-fidelity DNA; $68M Series B for synthetic biology and therapeutic applications.
About
Ansa Biotechnologies is a synthetic DNA synthesis company developing enzymatic DNA writing technology to overcome the length and quality limitations of chemical DNA synthesis. Founded in 2021 and headquartered in Emeryville, California, Ansa uses engineered terminal deoxynucleotidyl transferase (TdT) enzymes rather than phosphoramidite chemistry to build DNA strands, enabling synthesis of longer sequences with higher fidelity and fewer toxic reagents. The company emerged from research at UC Berkeley and Lawrence Berkeley National Laboratory.
Dominant browser-based collaborative UI design platform at ~$600M ARR and $12.5B valuation; Adobe's $20B acquisition blocked by regulators in 2023, Figma remains independent competing with Sketch and Adobe.
About
Figma is a San Francisco-based collaborative web-based product design platform that has become the dominant tool for UI/UX designers and product teams — enabling real-time multi-user collaboration on interface design, prototyping, and design system management directly in the browser without installing desktop software. Founded in 2012 by Dylan Field and Evan Wallace and backed by Sequoia, Greylock, and Andreessen Horowitz with over $330 million raised, Figma generated approximately $600 million in ARR in 2023, serving 4 million+ designers and product teams at companies including Microsoft, Airbnb, Twitter, and Uber. Adobe announced a $20 billion acquisition offer in 2022, which was blocked by regulators in 2023 — Figma remains independent.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.